Chardan Capital Initiates Coverage On Outlook Therapeutics with Buy Rating, Announces Price Target of $10

Benzinga · 09/13/2022 10:06
Chardan Capital analyst Daniil Gataulin initiates coverage on Outlook Therapeutics (NASDAQ:OTLK) with a Buy rating and announces Price Target of $10.